罗氏公布IMbrave150研究主要终点全新结果:“T+A”方案可显著改善晚期肝癌患者总生存期,中国数据表现尤佳

2021-01-12 罗氏 罗氏

2021年1月12日,罗氏宣布即将在本月举行的美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)上正式报告IMbrave150研究总生存(overall survival, OS)最新结果。

2021年1月12日,罗氏宣布即将在本月举行的美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)上正式报告IMbrave150研究总生存(overall survival, OS)最新结果。数据显示,接受泰圣奇®(Tecentriq®,通用名:阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。

IMbrave150是一项全球性III期、多中心、开放性研究,旨在评估“T+A”方案对比索拉非尼在既往未接受过系统性治疗的不可切除肝细胞癌(HCC)患者中的作用。2019年11月,罗氏在欧洲肿瘤内科学会亚洲大会(ESMO-ASIA)上公布了研究首要结果,两大主要终点——总生存期(OS)和无进展生存期(PFS)都达到了具有统计学意义和临床意义的改善。同时,IMbrave150试验的高质量PRO结果显示“T+A”方案可使患者报告的身体及角色功能和关键症状的恶化明显延迟,显著改善患者生活质量。
 
在经过中位时长15.6个月的随访后,最新分析结果表明,“T+A”方案可降低死亡风险34%,中位总生存期(mOS)达到19.2个月,优于此前标准方案的13.4个月(HR=0.66; 95% CI: 0.52–0.85);在中国亚群中,中位总生存期达到了24.0个月,优于此前标准方案的11.4个月(HR=0.53; 95% CI: 0.35-0.80)。最新总生存数据和无进展生存期(PFS)、客观有效率(ORR)等与首要分析结果一致。其安全性也与此前单独用药已知安全性特征一致,未发现任何新的安全信号。
 
IMbrave150研究的中国主要研究者、中国临床肿瘤学会(CSCO)副理事长秦叔逵教授指出:“2020年10月,‘T+A’免疫联合方案已正式在中国获批,目前也已被多个国内外权威临床指南以最优证据级别、最高推荐等级列为推荐疗法,充分证明了这一联合治疗药物/方案的突破性意义。值得一提的是,IMbrave150试验及扩展试验中的中国亚群虽然有着更高的乙肝感染率,同时具有大血管侵犯/肝外转移,甲胎蛋白≥400ng/ml等多种预后不良因素,仍然取得了出色的疗效,尤其是中位总生存期达到24.0个月,实现了晚期肝癌治疗的新突破,对中国广大患者而言具有里程碑式的重要意义!”

罗氏制药首席医学官、全球产品开发负责人Levi Garraway博士表示:“数据证实,在现有不可切除肝细胞癌的一线用药III期临床试验中,‘T+A’方案显示出了最长的总生存期。目前,该方案已在全球60多个国家和地区获批,结合首要分析结果,‘T+A’可为患者带来生存和生活质量的双重改善,是肝细胞癌治疗的重大进步。”



对照组:索拉非尼
PFS和所有缓解数据均由独立审查机构根据RECIST v1.1评估后报告
中位随访时间:15.6个月

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
    2021-09-18 沈敏

    阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
    2021-01-12 ZiaoZhao

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
    2021-01-12 lovetcm

    #肝癌#的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1052551, encodeId=89c0105255161, content=阿替利珠单抗)联合安维汀®(Avastin®,通用名:贝伐珠单抗)免疫联合疗法(以下简称“T+A”方案)治疗的患者中位总生存期(mOS)为19.2个月,其中中国亚群患者的中位总生存期达到24.0个月。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afe65591083, createdName=沈敏, createdTime=Sat Sep 18 12:41:34 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 26 21:16:00 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Feb 06 13:16:00 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915959, encodeId=6dbc91595985, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58b5452210, createdName=ZiaoZhao, createdTime=Tue Jan 12 17:26:46 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915932, encodeId=4ecf915932cc, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>的T+A方案是比较巧妙的组合,与前期的乐伐替尼+K药相比,更经济实惠。, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 12 15:49:32 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Tue Jan 12 15:16:00 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040338, encodeId=1b0010403389d, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon Jan 11 03:16:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
    2021-01-11 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

Eur Radiol:肝癌累及了肝静脉或下腔静脉,经动脉化疗栓塞后总生存率怎么样?

肝癌累及了肝静脉或下腔静脉,经动脉化疗栓塞后总生存率怎么样?

J Gastroenterology:直接作用抗病毒药可改善肝细胞癌治疗后的生存率和复发率

全球估计有180万人受到丙型肝炎病毒(HCV)感染的影响,同时丙肝也是肝细胞癌(HCC)的主要原因。

Nat Commun:肠道微生物群影响肝癌外周免疫反应

来自NAFLD-HCC微生物群的细菌提取物,而不是来自对照组的细菌提取物,会引起T细胞免疫抑制表型,其特征是调节性T细胞的扩张和CD8 + T细胞的衰减。

Signal Transduct Target Ther:浙大蔡秀军团队揭示外泌体介导的肝癌靶向耐药细胞间传播新机制

肝细胞癌(HCC)是最常见的原发性肝癌,在全球范围内,其发病率位于恶性肿瘤的第六位,其病死率在肿瘤相关死亡原因中的排名第四。对于晚期肝癌,索拉非尼是首个获得FDA批准的靶向治疗肝细胞肝癌的药物。

Science:最“安全”基因治疗载体似乎并不安全,血友病患者接受治疗后患上肝癌

荷兰生物制药公司uniQure的一项针对B型血友病的基因疗法被美国FDA叫停,起因是接受治疗后该患者患上了肝细胞癌。

CELL: 复旦大学樊嘉团队揭示早期复发肝癌的单细胞景观

我们对于与肝癌术后快速复发相关的分子机制仍知之甚少。对肿瘤复发的深入探索可以提高我们对肿瘤发生和进展相关机制的理解,有助于发现更有效的HCC治疗策略,包括免疫疗法。